Birmingham, AL, United States of America

Antonio Di Stasi

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: The UAB Research Foundation (The University of Alabama at Birmingham). Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Antonio Di Stasi. Retrieved from https://idiyas.com/inventor/antonio-di-stasi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Antonio Di Stasi: Innovator in Chimeric Antigen Receptors

Introduction

Antonio Di Stasi is a prominent inventor based in Birmingham, Alabama. He is known for his significant contributions to the field of immunotherapy, particularly through his innovative work on chimeric antigen receptors (CARs). His research focuses on developing advanced therapeutic methods for treating cancer.

Latest Patents

Antonio Di Stasi holds a patent for "Chimeric chlorotoxin receptors." This invention provides chimeric antigen receptors that comprise a fusion protein of chlorotoxin or any functional variant thereof. The CARs developed by Di Stasi may include additional moieties or domains, a transmembrane domain, and at least one intracellular signaling domain. These CTX-CARs can be expressed in host cells, such as immune effector cells, and are designed to treat patients with cancer by engineering immune cells to express these receptors.

Career Highlights

Di Stasi is associated with the UAB Research Foundation, where he continues to advance his research in immunotherapy. His work has the potential to significantly impact cancer treatment methodologies and improve patient outcomes.

Collaborations

Antonio Di Stasi collaborates with notable colleagues, including Lawrence S. Lamb and G. Yancey Gillespie. Their combined expertise enhances the research and development of innovative cancer therapies.

Conclusion

Antonio Di Stasi is a key figure in the development of chimeric antigen receptors, contributing to the advancement of cancer treatment. His innovative work at the UAB Research Foundation showcases the potential of engineered immune cells in modern medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…